This is a routine AGM filing with no material new information. The approved capital band authorizes potential future dilution of up to ~40% from current shares outstanding (102M to 143M), but this is a standard authorization and does not imply imminent issuance. Monitor upcoming H2 2026 pipeline catalysts (ABATE readouts, Phase 1 data) for meaningful stock-moving events.
Price Chart
Executive Summary
AC Immune held its Annual General Meeting on June 11, 2026, where shareholders approved all routine agenda items including 2025 financial statements, compensation reports, re-election of directors, and amendments to articles of association introducing a capital band (upper limit CHF 2,862,500) and increasing conditional share capital for employee benefit plans. The AGM presentation reviewed 2025 achievements and outlined upcoming pipeline catalysts for H2 2026, but no new material financial results, guidance changes, or corporate developments were disclosed.
Key Facts
- Shareholders approved 2025 IFRS consolidated financial statements and statutory financial statements.
- Shareholders endorsed 2025 compensation report (non-binding advisory vote).
- Net loss for 2025 was CHF 70,447K under IFRS.
- Directors re-elected: Martin Zügel (Chair), Renée Aguiar-Lucander, Monika Bütler, Carl June, Roy Twyman.
- Capital band introduced: upper limit CHF 2,862,500 (143,125,000 shares), lower limit CHF 2,202,018.50 (110,100,925 shares), authorizing Board to adjust capital until June 11, 2031.
- Conditional share capital for employee benefit plans increased from CHF 86,683.80 to CHF 150,000.00 (up to 7,500,000 shares).
- Cash resources of CHF 74.8 million (~USD 94 million) as of March 31, 2026, provide runway into Q4 2027.
- 2026 annual cash burn guidance: CHF 55m-65m.
- Partner payments expected in 2026: ACI-24.060 (Takeda) $12 million milestone; Mor-Tau (Lilly) CHF 10 million upfront.
- Upcoming H2 2026 catalysts include ABATE Phase 2 readouts (12-month treatment, AD3 Abeta PET) and Phase 1 data for NLRP3 inhibitor and a-syn/TDP-43 PET tracers.
Financial Impact
No new financial data beyond previously reported 2025 results. Cash position of CHF 74.8M (USD 94M) as of March 31, 2026, with operating runway into Q4 2027. 2026 cash burn guidance unchanged at CHF 55-65 million.
Risk Factors
- Capital band authorization could enable future dilutive equity issuance.
- Pre-revenue clinical-stage company with no approved products; pipeline dependent on clinical trial outcomes.
- Cash runway only into Q4 2027; additional financing likely needed before reaching profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-008857 |
| Document: dp248284_6k-agmresults.htm | 0000950103-26-008857 |
| Document: 0000950103-26-008857-index-headers.html | 0000950103-26-008857 |
| Document: 0000950103-26-008857-index.html | 0000950103-26-008857 |
| Document: 0000950103-26-008857.txt | 0000950103-26-008857 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.31 (−5.71%) |
Oct 9, 2026 17d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.31 (−7.60%) |
Oct 2, 2026 24d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.31 (−15.23%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.31 (−18.37%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.31 (−21.16%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.31 (−12.50%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.31 (−12.50%) |
Aug 11, 2026 10w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.31 (−9.06%) |
Aug 11, 2026 10w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.31 (−9.06%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.31 (+0.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers